Annual cost of erectile dysfunction to UK society

PharmacoEconomics

Volumn 16, Issue 6, 1999, Pages 699-709

  Plumb, Jonathan M ^a   Guest, Julian F ^a  

^a CATALYST Health Economics Consultants   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANGINA PECTORIS AGENT; ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; PAPAVERINE; PROSTAGLANDIN E1; SILDENAFIL;

ADULT; AGED; ARTICLE; ERECTILE DYSFUNCTION; HUMAN; INTRACAVERNOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; NATIONAL HEALTH SERVICE; OUTPATIENT CARE; PENIS PROSTHESIS; PRIORITY JOURNAL; QUESTIONNAIRE; SOCIOECONOMICS;

EID: 0033404681     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-199916060-00008     Document Type: Article

References (33)

1. American Psychiatric Association (APA). Diagnostic and statistical manual of mental disorder. Washington, DC: APA, 1994
2. Drane RJ, Goldstein I, Saenz de Tejada I. Impotence. N Engl J Med 1989; 321: 1648-59
3. World Health Organization (WHO). F52.2 failure of genital response. The ICD-10 classification of mental and behavioural disorders: diagnostic criteria for research. Geneva: WHO, 1993
4. Hedlund H, Hedlund P. Pharmacotherapy in erectile dysfunction: agents for self-injection programs and alternative application models. Scand J Urol Nephrol 1996; 179: SS129-38
5. Benet AE, Melman A. The epidemiology of erectile dysfunction. Urol Clin North Am 1995; 2 (4): 699-709
6. Bortololli A, Parazzini F, Colli E, et al. The epidemiology of erectile dysfunction and its risk factors. Int J Androl 1997; 20: 323-34
7. Burls A, Gold L, Simpson S, et al. Sildenafil: an oral drug for the treatment of male erectile dysfunction. Birmingham: University of Birmingham, 1998. DPHE report no.: 12, InterDEC report no. 28
8. Feldman H, Goldstein I, Hartzichristou DG, et al. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Ageing Study. J Urol 1994; 151: 54-61
9. Kinsey AC, Pomeroy WB, Martin CE. Sexual behaviour in the human male. Philadelphia (PA): W.B. Saunders Company, 1948
10. Benet AE, Melman A. The epidemiology of erectile dysfunction. Urol Clin North Am 1995; 22: 699-709
11. Department of Health. Viagra - NHS prescription proposal announced [press release]. London: Department of Health, 1999 Jan 21
12. NHS Executive. Treatment for impotence. Leeds: Department of Health, 1999 May 7. Health Service Circular no.: HSC 1999/115
13. Doctors' Independent Network (DIN-LINK) database. Surrey: Compufile Ltd, 1998
14. Martin RM. The doctors independent network database: background and methodology. Pharm Med 1995; 9: 165-76
15. Intercontinental Medical Statistics (IMS) Ltd. Survey of retail sales 1997/98. Middlesex: IMS Ltd., 1998
16. Taylor Nelson Sofres Healthcare. Survey of prescriptions dispensed at retail pharmacies, 1997/98. Surrey: Taylor Nelson Sofres Healthcare, 1998
17. Department of Health. Hospital episode statistics England, 1994/95. London: HMSO, 1996
18. Netten A, Dennett J. Unit costs of health and social care 1997. Canterbury: University of Kent, Personal Social Services Research Unit, 1997
19. Bruce NJ, McCloskey EV, Kanis JA, et al. Economic impact of using clodronate in the management of patients with multiple myeloma. Br J Haematol 1999; 104: 358-64
20. Chartered Institute of Public Finance & Accountancy (CIPFA). Health database. London: CIPFA, 1997
21. Monthly index of medical specialities. 1998 ed. London: Haymarket Publications Ltd, 1998
22. Rosen RC, Riley A, Wagner G, et al. The International Index of Erectile Function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997; 49 (6): 822-30
23. The Henley Centre UK Forecasts, October 1998. London: The Henley Centre UK Forecasts, 1998
24. Kind P. The EuroQol instrument: an index of health-related quality of life. In: Spilker B, editor. Quality of life and pharmacoeconomics in clinical trials. Philadelphia (PA): Lippincott-Raven, 1996
25. Shabsigh R, Klein LT, Seidman S, et al. Increased incidence of depressive symptoms in men with erectile dysfunction. Urology 1998; 52 (5): 848-52
26. Jhaveri FM, Rutledge R, Carson CC. Penile prosthesis implantation surgery: a statewide population based analysis of 2354 patients. Int J Impot Res 1998; 10 (4): 251-4
27. Guest JF. The annual cost of chronic obstructive pulmonary disease to the UK's National Health Service. Dis Manag Health Outcomes 1999; 5 (2): 93-100
28. Guest JF, Cookson RF. Cost of schizophrenia to UK society: an incidence-based cost of illness model for the first 5 years following diagnosis. Pharmacoeconomics 1999; 15 (6): 597-610
29. The Impotence Association. Key findings of the Impotence Association Patient and Partner Erectile Dysfunction Survey [factsheet]. London: The Impotence Association, 1997
30. Strachan DP. Epidemiology: a British perspective. In: Calverley P, Pride N, editors. Chronic obstructive pulmonary disease. London: Chapman and Hall, 1995: 47-67
31. Goldstein I, Lue TF, Padma-Nathan H, et al. Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med 1998; 338: 1397-404
32. Boolell M, Gepi-Attee S, Gingell CJ, et al. Sildenafil: a novel effective oral therapy for male erectile dysfunction. Br J Urol 1996; 78: 257-61
33. 1997 census. Key population and vital statistics: Local and Health Authority area population and vital statistics by area of usual residence in the United Kingdom, 1997. London: Office of National Statistics, 1999